Sabon Maganin Ciwon daji na Zantrene yana kare zuciya daga mutuwa

• Magungunan Race Oncology na Zantrene da aka nuna don kare ƙwayoyin tsokar zuciyar ɗan adam daga mutuwar chemotherapy wanda ya haifar da anthracycline. Anthracycline's sune magungunan da aka fi amfani da su kuma masu tasiri na rigakafin ciwon daji, duk da haka suna iya haifar da mummunar lalacewar zuciya. 
• Binciken na yau da kullun ya kuma nuna ikon Zantrene don yin aiki tare da anthracyclines da ake da su don kashe ƙwayoyin cutar kansar nono. 
• Saboda mahimmancin binciken, Zantrene za a bi da shi cikin sauri zuwa asibitin tare da gwajin Phase 2b da aka tsara don 2022 a cikin masu fama da cutar kansar nono a cikin haɗarin cutar anthracycline da ke haifar da lalacewar zuciya. 
• Yana ba da yuwuwar girman dawowar asibiti da kasuwanci daga sabbin hanyoyin Zantrene/anthracycline da haɗuwa.

Wannan shi ne karo na farko da wani magani ya nuna ikon da ake yi wa cutar kansa duka da kuma kare zuciya daga lalacewar anthracycline. Wannan binciken yana ba da sabon bege ga miliyoyin masu fama da cutar kansa a duk duniya waɗanda ke yin maganin chemotherapy tare da anthracyclines kuma suna cikin haɗarin haɗari da lalacewa ta dindindin a zukatansu. 

Anthracyclines an san su da yawa a matsayin mafi tasiri maganin ciwon daji da aka taɓa samu kuma ana amfani da su a cikin nau'in ciwon daji fiye da kowane nau'in maganin ciwon daji.^[1], ciki har da cutar sankarar bargo, lymphomas, neuroblastoma, koda, hanta, ciki, uterine, thyroid, ovarian, sarcomas, mafitsara, huhu da kuma nono. Duk da haka, tsoro game da illar cutar anthracyclines a cikin zuciya ya sa yawancin likitocin ciwon daji sun iyakance amfani da waɗannan magunguna masu tasiri. Ganowar tseren yana da yuwuwar kawo sauyi ga amfani da anthracyclines ta hanyar kyale likitocin cutar kanjamau su yi amfani da waɗannan magunguna masu ƙarfi zuwa cikakkiyar damar rigakafin cutar kansa ba tare da tsoron cutarwa ta dindindin ba ga zuciya.

A Zantrene^® Mashahurin masu binciken cututtukan zuciya, Farfesa Aaron Sverdlov da Doan Ngo ne ke jagorantar shirin binciken lafiyar zuciya, tare da haɗin gwiwar Farfesa Farfesa Nikki Verrills na Jami'ar Newcastle.

Mataimakin Farfesa Aaron Sverdlov ya ce: "Har zuwa yau, ra'ayin yuwuwar hanyoyin kwantar da hankali na kansa waɗanda ba kawai ba na cardiotoxic bane amma, a zahiri, ba a ƙididdige abubuwan kariya na cardio-protective ba ko ma nishadantarwa, galibi saboda 'hanyoyin ƙayyadaddun cututtuka a cikin kiwon lafiya. Sakamakonmu ya nuna cewa Zantrene, ingantaccen maganin ciwon daji, na iya ba da kariya gaba ɗaya daga tasirin mai guba akan zuciya daga ɗayan magungunan chemotherapy da aka fi amfani da su, doxorubicin. Wannan ita ce shaida ta farko ta irinta don nuna cewa akwai wani magani wanda duka biyun ke kaiwa kansa hari kuma yana kare zuciya! Wannan yana da yuwuwar inganta sakamakon kiwon lafiya ga marasa lafiya da yawa masu fama da cutar kansa da waɗanda suka tsira ta hanyar inganta maganin cutar kansa tare da hana haɓakar cututtukan zuciya.”

Yayin da wannan sabon bincike ne mai ban sha'awa, Zantrene^® (bisantrene dihydrochloride) yana da dogon tarihin asibiti, wanda aka haɓaka shi a cikin 1970s azaman madadin amintaccen zuciya ga anthracyclines[2] kafin amincewa a Faransa a cikin 1990s. Yayin da aka tabbatar da ingantacciyar lafiyar zuciya ta Zantrene a cikin gwaje-gwajen asibiti sama da 50^[3], , Tambayar ko Zantrene zai iya taimakawa wajen hana lalacewar zuciya ta hanyar anthracyclines ba a taba magance ba.

Da yake tsokaci game da sabon sakamakon binciken, babban jami'in kimiyya na Race, Dokta Daniel Tillett ya ce: "Don gano cewa Zantrene na iya kare zuciya daga chemotherapy yayin da kuma yana kashe cututtukan daji mafi kyau shine babban sakamako 'mafi kyaun duniyoyin biyu'. Ganin cewa ana amfani da anthracyclines a cikin miliyoyin masu fama da cutar kansa kowace shekara, yana da wahala a wuce gona da iri na asibiti da kasuwancin wannan ci gaban!

karshe

• A cikin wannan ƙayyadaddun samfurin, Zantrene yana kare ƙwayoyin tsokar zuciya daga lalacewa ta hanyar doxorubicin yayin aiki tare da anthracyclines don mafi kyawun kashe ƙwayoyin kansar nono. 
• Race ta ƙaddamar da takardar izinin haƙƙin mallaka wanda ke magance haɗin Zantrene tare da anthracycline don kare zuciyar marasa lafiya. Wannan lamban kira (idan an ba shi) zai ba da kariya ga haɗin magunguna da amfani da shi na asibiti har zuwa 2041. 
• Wannan sabon binciken kariyar zuciya zai ci gaba da sauri zuwa asibiti. Babban tarihin asibiti na Zantrene yana ba da damar wannan haɗin don haɓaka cikin sauri a asibiti. 
• Ana ci gaba da tattaunawa mai zurfi tare da likitoci a Ostiraliya don gudanar da gwajin asibiti na Phase 2b a cikin marasa lafiya da ke fama da ciwon nono a cikin haɗari mai tsanani na lalacewar zuciya ta anthracycline. 
• Wannan binciken yana buɗe sabbin damar kasuwa don Zantrene na irin wannan damar na asibiti da kasuwanci zuwa farkon binciken da aka gano cewa Zantrene shine mai hana FTO mai ƙarfi.

Next Matakai

• Za a gudanar da karatun dabbobi a cikin Q4 CY2021/Q1CY2022. 
• Ƙarin bincike na musamman don bincika idan Zantrene zai iya kare zuciya daga lalacewa ta wasu magungunan chemotherapeutic waɗanda kuma aka sani suna haifar da lalacewar zuciya. 
• Ƙarin karatu don sanin tsarin kwayoyin halittar Zantrene's cardio-protective ayyuka. Wannan na iya ba da damar gano ƙarin ayyukan kariya na Zantrene. 
• Haɓaka sabbin hanyoyin haɗin magunguna tare da ingantattun ƙimar asibiti da kasuwanci. 
• Ƙaddamar da gwaji na asibiti na 2b na ciwon nono a cikin 2022.